ESMO World Congress on Gastrointestinal Cancer 2016

Oncology Meeting Resources

29 Jun - 02 Jul 2016, Barcelona, Spain

World GI 2016 Square Image

The ESMO World Congress on Gastrointestinal Cancer is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours.

Abstracts, presentations and webcasts from the ESMO World GI 2016 Congress are now available here to ESMO members. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.





Format available

http://oncologypro.esmo.org/Meeting-Resourc...-removal-of-retroperitoneal-tumors-of-pelvis

Surgical treatment of retroperitoneal tumors of pelvis area is a difficult section of modern oncology. Equally important is the question how to complete the surgical treatment when combined with the removal of tumors.

Date: 29 Jun 2016
Presenter: A. Abdujapparov
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...atic-Colorectal-Cancer-mCRC-elderly-patients

The Observatory of Cancer was created in 2003 by the Regional Health Agency in Western France (Bretagne and Pays de la Loire). It collects data from almost 50 public hospitals and private institutions....

Date: 29 Jun 2016
Presenter: J.-P. Metges
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...-bladder-cancer-regional-cancer-centre-study

Gallbladder cancer (GC) is associated with a poor prognosis.The goal of palliation for advanced GBC is relief of pain and jaundice along with prolongation of life.

Date: 29 Jun 2016
Presenter: P. Kumari
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...on-of-gastric-cancer-cells-via-FOXQ1-pathway

Tumor-associated macrophages (TAMs) promoted the invasion of gastric cancer cells, but the exactly mechanism has not been clarified. FOXQ1 is a prognostic marker for patients with gastric cancer.

Date: 29 Jun 2016
Presenter: J. Zhang
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...-unresectable-advanced-gall-bladder-cancer-A

Gallbladder cancer (GBC) is an uncommon but highly fatal malignancy Gallbladder represent the most common cancer among biliary tree, complete cure possible only with surgery, but most patients presents...

Date: 29 Jun 2016
Presenter: P. Khatri
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...-and-outcome-of-pancreatic-cancer-in-Tunisia

Pancreatic cancer is the fifth most common cause of cancer death worldwide. Few data are available on its epidemiology and outcome in Tunisia. This study reports epidemiological, clinical features and...

Date: 29 Jun 2016
Presenter: M. Nasri
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...-cancer-good-prognostic-sign-Our-experiences

Gastric cancer is the fifth most frequent cancer in Bosnia and Herzegovina [1]. Because of the high mortality rates, ranging up to 80% in five years, [2] gastric cancer represents a major public health problem.

Date: 29 Jun 2016
Presenter: M. Vještica
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...lly-advanced-or-metastatic-pancreatic-cancer

Single-agent gemcitabine (GEM) has been considered for many years as the standard first-line treatment for advanced pancreatic cancer. Recently studies show a trend towards improved survival when using a gemcitabine doublet.

Date: 29 Jun 2016
Presenter: P. Khatri
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...00-mg-in-advanced-pancreatic-cancer-patients

Erlotinib selectively inhibits the intracellular phosphorylation of human EGFR-Type 1, expressed on the cell surface of normal and cancer cells, thus preventing the signal transduction and resulting...

Date: 29 Jun 2016
Presenter: A. Sahmanovic
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...therapy-for-liver-only-colorectal-metastases

Liver resection for colorectal liver metastases (CRLM) is now widely accepted in selected cases. However, the surgical strategy can become challenging when these lesions are localized in areas of high risk for bleeding, e.

Date: 29 Jun 2016
Presenter: M. Costa Neves
Resources: Abstract